Company Background

PRIME exits and American Healthcare Capital has been exclusively engaged to market a profitable, multi-state clinical laboratory for sale offering diagnostic testing services with a growing tech-enabled footprint. The Company operates from a centralized CLIA-certified lab and serves a broad network of physician groups and health plans across the Northeast U.S.

Founded in 2020, the business has demonstrated strong financial performance and operational efficiency, underpinned by a highly credentialed staff, insurance panel relationships, and a full suite of routine and specialized testing capabilities. The Company is in the final stages of launching a proprietary mobile diagnostics app that enables patients to request in-home blood draws, track technician arrival, upload test orders, and receive results digitally — a direct-to-consumer layer poised to unlock significant scale and margin expansion.

Financial Information

• 2024 Revenue: ~$4.5 million

• 2024 Adjusted EBITDA: ~$1.52 million

• 2024 EBITDA Margin: ~34%

• 2023 Revenue: $5.32 million

• 2023 Adjusted EBITDA: $2.24 million

The modest revenue decline in 2024 is attributable to two discrete, non-recurring issues: (1) a reduction in COVID-related testing volume as market conditions normalized, and (2) a temporary claims routing issue with a major commercial insurer that resulted in reimbursements being sent to patients rather than the Company. That issue has since been fully resolved, and the business has implemented a formal protocol to recover those payments — the majority of which are expected to be collected in the near term. 2025 is projected to be a stronger year with revenue of $4.7 million and EBITDA of $1.8 million.

Investment Highlights

• High-Margin Diagnostic Platform with strong payer relationships and recurring volume

• Tech-Enabled Delivery Model with mobile app rollout underway

• Lean Cost Structure supporting consistent cash flow and scalability

• Founder-Operated with willingness to stay on post-close

• Clear Expansion Path via direct-to-consumer diagnostics, geographic growth, and additional test panels

Asking Price

The asking price for this opportunity is $10 million.